Changes in bone turnover during tibolone treatment.
OBJECTIVE
An open study was carried out to evaluate changes in bone remodeling markers such as N-telopeptide (NTx), tartrate-resistant acid phosphatase (TRAP), total alkaline phosphatase (TAP), and bone alkaline phosphatase (BAP) during a 1-year continuous tibolone treatment in postmenopausal women.


METHODS
Thirty-six postmenopausal women were recruited for receiving tibolone 2.5 mg per day for 1 year. Densitometry and determination of biochemical markers of bone metabolism in serum and urine were performed at 1, 3, 6, and 12 months.


RESULTS
Comparing baseline with 12 month's values, BAP and all resorption markers decreased significantly. NTx began to decrease since the initiation of the treatment (baseline: 74.4 +/- 5.3; 1 month: 57.5 +/- 4.2; 12 months: 36.6 +/- 2.8). BAP increased at the first month (baseline: 37.3 +/- 2.1; 1 month: 42.6 +/- 3.0) but diminished in the following months (12 months: 23.1 +/- 1.5). TAP started to decrease significantly only after 6 months of treatment (baseline: 37.3 +/- 2.1; 12 months: 31.4 +/- 2.3) and TRAP after 3 months (baseline: 9.8 +/- 0.4; 6 months: 9.1 +/- 0.5; 12 months: 8.2 +/- 0.4). Normal bone mineral density at distal and ultradistal forearm was maintained during the 1-year treatment (baseline: 0.42 +/- 0.01; 12 months: 0.42 +/- 0.01 and baseline: 0.33 +/- 0.01; 12 months: 0.33 +/- 0.01, respectively).


CONCLUSIONS
The use of tibolone 2.5 mg per day diminished progressively and significantly bone resorption and formation markers during 1-year treatment period.
Riera-Espinoza
Gregorio
G
UNILIME, Universidad de Carabobo, Hospital Universitario Dr. Angel Larralde, IVSS, Valencia, Venezuela. griera@net-uno.net
Ramos
Jenny
J
Carvajal
Rosalía
R
Belzares
Emma
E
Stanbury
Guadalupe
G
Farías
Rosa
R
Valderrama
Inés
I
Alvarez
Kelia
K
Riera-González
Gregorio
G
D000135:Acid Phosphatase / Q000032:analysis; D000469:Alkaline Phosphatase / Q000032:analysis; D045930:Anabolic Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000032:analysis; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D016723:Bone Remodeling / Q000187:drug effects*; D003094:Collagen / Q000032:analysis; D024042:Collagen Type I; D004334:Drug Administration Schedule; D005260:Female; D005542:Forearm; D006801:Humans; D007527:Isoenzymes / Q000032:analysis; D008875:Middle Aged; D009652:Norpregnenes / Q000627:therapeutic use*; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D010455:Peptides / Q000032:analysis; D000071681:Tartrate-Resistant Acid Phosphatase
D045930:Anabolic Agents; D015415:Biomarkers; D024042:Collagen Type I; D007527:Isoenzymes; D009652:Norpregnenes; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D003094:Collagen; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase; C027385:tibolone